title: Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial.
abstract: OBJECTIVE
  To compare the efficacy of two doses of lansoprazole with that of placebo in preventing recurrence of erosive esophagitis in a 12-month period.
  
  
  METHODS
  Randomized, double-blind, parallel, placebo-controlled trial.
  
  
  METHODS
  25 U.S. medical centers.
  
  
  METHODS
  173 patients with documented healing of erosive esophagitis after 8 weeks of acid-suppressing therapy.
  
  
  METHODS
  Lansoprazole, 15 mg or 30 mg, or placebo once daily for as long as 12 months.
  
  
  METHODS
  Endoscopy and symptom evaluation after 1, 2, 3, 6, 9, and 12 months of treatment. Endoscopy was also done whenever symptoms suggested erosive changes.
  
  
  RESULTS
  Lansoprazole was significantly superior to placebo in maintaining healing and preventing recurrence of symptoms. By month 1, 45% of placebo recipients remained healed compared with more than 90% of patients in either lansoprazole group. By month 12, only 24% of placebo recipients remained healed compared with 79% of patients receiving 15 mg of lansoprazole and 90% of patients receiving 30 mg of lansoprazole. During the same period, 35% of placebo recipients remained asymptomatic compared with 72% of recipients of 15 mg of lansoprazole and 67% of recipients of 30 mg of lansoprazole. The 15-mg and 30-mg lansoprazole doses did not differ significantly in maintaining healing and controlling symptoms. Follow-up after recurrence of erosion indicated that during the 12 months, 35% of placebo recipients and 2% of lansoprazole recipients had three or more recurrences.
  
  
  CONCLUSIONS
  Lansoprazole effectively maintains healing of erosive esophagitis. The 15-mg and 30-mg lansoprazole doses did not differ significantly for use as maintenance treatment.
authors.affiliation: University of Oklahoma College of Medicine, Oklahoma City, USA.
authors.forename: M
authors.initials: M
authors.lastname: Robinson
authors.forename: F
authors.initials: F
authors.lastname: Lanza
authors.forename: D
authors.initials: D
authors.lastname: Avner
authors.forename: M
authors.initials: M
authors.lastname: Haber
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004311:Double-Blind Method; D004942:Esophagitis, Peptic / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D004945:Esophagoscopy; D005260:Female; D005500:Follow-Up Studies; D005744:Gastric Acid / Q000378:metabolism; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D010919:Placebos; D054328:Proton Pump Inhibitors; D012008:Recurrence; D012636:Secretory Rate / Q000187:drug effects
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D010919:Placebos; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D009853:Omeprazole